Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1994 3
1995 3
1996 2
1997 2
1998 4
1999 4
2000 3
2001 9
2002 3
2003 2
2004 2
2005 2
2006 3
2007 2
2008 1
2013 5
2014 8
2015 10
2016 9
2017 11
2018 3
2019 13
2020 22
2021 17
2022 14
2023 13
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

160 results

Results by year

Filters applied: . Clear all
Page 1
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.
Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, Musso M, Giebel S, Uzay A, Langmuir P, Hollaender N, Gowda M, Stefanelli T, Lee SJ, Teshima T, Locatelli F; REACH3 Investigators. Zeiser R, et al. N Engl J Med. 2021 Jul 15;385(3):228-238. doi: 10.1056/NEJMoa2033122. N Engl J Med. 2021. PMID: 34260836 Clinical Trial.
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.
Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, Szer J, Wagner EM, Zuckerman T, Mahuzier B, Xu J, Wilke C, Gandhi KK, Socié G; REACH2 Trial Group. Zeiser R, et al. N Engl J Med. 2020 May 7;382(19):1800-1810. doi: 10.1056/NEJMoa1917635. Epub 2020 Apr 22. N Engl J Med. 2020. PMID: 32320566 Clinical Trial.
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, Raderer M, Mayer J, Pereira J, Tumyan G, Okamoto R, Nakahara S, Hu P, Appiani C, Nemat S, Cavalli F; LYM-3002 investigators. Robak T, et al. Lancet Oncol. 2018 Nov;19(11):1449-1458. doi: 10.1016/S1470-2045(18)30685-5. Epub 2018 Oct 19. Lancet Oncol. 2018. PMID: 30348538 Clinical Trial.
Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.
Trappe RU, Dierickx D, Zimmermann H, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, Dührsen U, Reinke P, Verhoef G, Subklewe M, Hüttmann A, Tousseyn T, Salles G, Kliem V, Hauser IA, Tarella C, Van Den Neste E, Gheysens O, Anagnostopoulos I, Leblond V, Riess H, Choquet S. Trappe RU, et al. Among authors: zaucha jm. J Clin Oncol. 2017 Feb 10;35(5):536-543. doi: 10.1200/JCO.2016.69.3564. Epub 2016 Dec 19. J Clin Oncol. 2017. PMID: 27992268 Clinical Trial.
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.
Dytfeld D, Wróbel T, Jamroziak K, Kubicki T, Robak P, Walter-Croneck A, Czyż J, Tyczyńska A, Druzd-Sitek A, Giannopoulos K, Nowicki A, Szczepaniak T, Łojko-Dankowska A, Matuszak M, Gil L, Puła B, Rybka J, Majcherek M, Usnarska-Zubkiewicz L, Szukalski Ł, Końska A, Zaucha JM, Walewski J, Mikulski D, Czabak O, Robak T, Lahoud OB, Zonder JA, Griffith K, Stefka A, Major A, Derman BA, Jakubowiak AJ. Dytfeld D, et al. Among authors: zaucha jm. Lancet Oncol. 2023 Feb;24(2):139-150. doi: 10.1016/S1470-2045(22)00738-0. Epub 2023 Jan 12. Lancet Oncol. 2023. PMID: 36642080 Free PMC article. Clinical Trial.
Hodgkin Lymphoma: Recent Progress in Overall Management.
El-Galaly TC, Cottereau AS, Condoluci A, Rossi D, Zaucha JM, Sureda A, Cheson B, Gallamini A. El-Galaly TC, et al. Among authors: zaucha jm. In: Gallamini A, Juweid M, editors. Lymphoma [Internet]. Brisbane (AU): Exon Publications; 2021 Dec 28. Chapter 6. In: Gallamini A, Juweid M, editors. Lymphoma [Internet]. Brisbane (AU): Exon Publications; 2021 Dec 28. Chapter 6. PMID: 35226430 Free Books & Documents. Review.
Resurrecting the Dead (Molecules).
Zaucha J, Heddle JG. Zaucha J, et al. Comput Struct Biotechnol J. 2017 May 30;15:351-358. doi: 10.1016/j.csbj.2017.05.002. eCollection 2017. Comput Struct Biotechnol J. 2017. PMID: 28652896 Free PMC article. Review.
Identification of novel genetic loci for risk of multiple myeloma by functional annotation.
Macauda A, Briem K, Clay-Gilmour A, Cozen W, Försti A, Giaccherini M, Corradi C, Sainz J, Niazi Y, Ter Horst R, Li Y, Netea MG, Vogel U, Hemminki K, Slager SL, Varkonyi J, Andersen V, Iskierka-Jazdzewska E, Mártinez-Lopez J, Zaucha J, Camp NJ, Rajkumar SV, Druzd-Sitek A, Bhatti P, Chanock SJ, Kumar SK, Subocz E, Mazur G, Landi S, Machiela MJ, Jerez A, Norman AD, Hildebrandt MAT, Kadar K, Berndt SI, Ziv E, Buda G, Nagler A, Dumontet C, Raźny M, Watek M, Butrym A, Grzasko N, Dudzinski M, Rybicka-Ramos M, Matera EL, García-Sanz R, Goldschmidt H, Jamroziak K, Jurczyszyn A, Clavero E, Giles GG, Pelosini M, Zawirska D, Kruszewski M, Marques H, Haastrup E, Sánchez-Maldonado JM, Bertsch U, Rymko M, Raab MS, Brown EE, Hofmann JN, Vachon C, Campa D, Canzian F. Macauda A, et al. Among authors: zaucha j. Leukemia. 2023 Nov;37(11):2326-2329. doi: 10.1038/s41375-023-02022-8. Epub 2023 Sep 18. Leukemia. 2023. PMID: 37723249 Free PMC article. No abstract available.
SARS‑CoV‑2-induced remission of advanced classical Hodgkin lymphoma.
Kurlapski M, Romanowicz G, Taszner M, Zaucha JM. Kurlapski M, et al. Among authors: zaucha jm. Pol Arch Intern Med. 2022 Aug 22;132(7-8):16266. doi: 10.20452/pamw.16266. Epub 2022 May 25. Pol Arch Intern Med. 2022. PMID: 35620893 Free article. No abstract available.
160 results